Overview

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Status:
Active, not recruiting

Trial end date:
2022-06-02

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following Standard of Care (SoC) platinum-based chemotherapy with Durvalumab as first-line treatment in patients with Stage IV non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Cisplatin
Durvalumab
Gemcitabine
Olaparib
Paclitaxel
Pemetrexed